Quality of Life Assessment with EORTC QLQ in Patients with Multiple Myeloma: Multicenter Study

GEM�C�, Ali �hsan; SER�N, �stemi; EROL, Vedat Bu�ra; DO�U, Mehmet Hilmi; �NCE, �dris; EREN, Rafet; TEK�NALP, Atakan; KARAKU�, Volkan; KO� EROL, �klil Nur; ARSLAN, Zeynep Ece; TAY, Zekiye Nur; TUNCER, Elif Nur; SEV�ND�K, �m�r G�kmen

5/3Current Issue Ahead of print Archive Most Accessed Articles

Index

Applications

Membership

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

Quality of Life Assessment with EORTC QLQ in Patients with Multiple Myeloma: Multicenter Study [Forbes J Med]

Forbes J Med. 2022; 3(2): 165-172 | DOI: 10.4274/forbes.galenos.2022.04274

Quality of Life Assessment with EORTC QLQ in Patients with Multiple Myeloma: Multicenter Study

Ali �hsan GEM�C�¹, �stemi SER�N², Vedat Bu�ra EROL³, Mehmet Hilmi DO�U⁴, �dris �NCE⁵, Rafet EREN⁴, Atakan TEK�NALP⁶, Volkan KARAKU�⁷, �klil Nur KO� EROL⁸, Zeynep Ece ARSLAN⁸, Zekiye Nur TAY⁸, Elif Nur TUNCER⁸, �m�r G�kmen SEV�ND�K¹
¹�stanbul Medipol University Faculty of Medicine, Department of Hematology, �stanbul, Turkey
²University of Health Sciences Turkey, �stanbul Training and Research Hospital, Clinic of Hematology, �stanbul, Turkey
³�stanbul Medipol University Faculty of Medicine, Department of Internal Medicine, �stanbul, Turkey
⁴�stinye University Faculty of Medicine, Liv Hospital Ulus, Department of Internal Medicine and Hematology, �stanbul, Turkey
⁵University of Health Sciences Turkey, Dr. Ersin Arslan Training and Research Hospital, Clinic of Internal Medicine, Gaziantep, Turkey
⁶Necmettin Erbakan University Faculty of Medicine, Department of Hematology, Konya, Turkey
⁷Alaattin Keykubat University Faculty of Medicine, Department of Hematology, Alanya, Turkey
⁸�stanbul Medipol University Faculty of Medicine, �stanbul, Turkey

Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC Quality of Life Questionnaire Consisting of 30 Questions �EORTC QLQ-C30� and the Quality of Life Questionnaire Multiple Myeloma Module �QLQ-MY20�, we aimed to obtain data on quality of life in MM patients in a representative sample of the general population of our country.
Methods: One hundred sixty eight patients from 6 different centers followed between 2018-2020 were included in the study. The QLQ-C30, and the QLQ-MY20 questionnaires specific for MM patients were used and the results were reported statistically.
Results: Seventy eight (46%) of the patients were female, while 90 (54%) were male. The median age was 64 (22-84). When the findings were analysed, it was found that there was a greater effect on the symptom scale compared to the functional scale.
Conclusion: The importance of the treatment-related side effect management, together with the adequate administration of appropriate symptomatic treatment in holistic treatment management were emphasized as effective factors in terms of the QoL of patients with MM.

Keywords: Multiple myeloma, quality of life, chemotherapy

Multipl Miyelom Tan�l� Hastalarda EORTC QLQ ile Ya�am Kalitesi De�erlendirmesi: �ok Merkezli �al��ma

Ali �hsan GEM�C�¹, �stemi SER�N², Vedat Bu�ra EROL³, Mehmet Hilmi DO�U⁴, �dris �NCE⁵, Rafet EREN⁴, Atakan TEK�NALP⁶, Volkan KARAKU�⁷, �klil Nur KO� EROL⁸, Zeynep Ece ARSLAN⁸, Zekiye Nur TAY⁸, Elif Nur TUNCER⁸, �m�r G�kmen SEV�ND�K¹
¹�stanbul Medipol �niversitesi, Hematoloji Bilim Dal�, �stanbul, T�RK�YE
²Sa�l�k Bilimleri �niversitesi, �stanbul E�itim ve Ara�t�rma Hastanesi, Hematoloji Klini�i, �stanbul, T�RK�YE
³�stanbul Medipol �niversitesi, �� Hastal�klar� Anabilim Dal�, �stanbul, T�RK�YE
⁴�stinye �niversitesi, �� Hastal�klar� ve Hematoloji Birimi, Liv Hospital Ulus Hematoloji Klini�i, �stanbul, T�RK�YE
⁵Sa�l�k Bilimleri �niversitesi, Dr. Ersin Arslan E�itim ve Ara�t�rma Hastanesi, Gaziantep, T�RK�YE
⁶Necmettin Erbakan �niversitesi, Hematoloji Bilim Dal�, Konya, T�RK�YE
⁷Alaattin Keykubat �niversitesi, Hematoloji Bilim Dal�, Alanya, T�RK�YE
⁸�stanbul Medipol �niversitesi, T�p Fak�ltesi, �stanbul, T�RK�YE

Ama�: Hem tedavi s�resinin uzunlu�u, hem de tedavide kullan�lan ajanlar�n �e�itlili�i multipl miyelomlu (MM) hastalar�n ya�am kalitesini (YK) �nemli �l��de etkiler. Otuz sorudan olu�an EORTC Ya�am Kalitesi Anketi �EORTC QLQ-C30� ve Ya�am Kalitesi Anketi-Multipl Miyelom Mod�l� �QLQ-MY20� yard�m�yla MM hastalar�nda ya�am kalitesine ili�kin verileri elde etmeyi ama�lad�k.
Y�ntem: 2018-2020 y�llar� aras�nda takip edilen, 6 farkl� merkezden 168 hasta �al��maya dahil edildi. MM hastalar�na �zel QLQ-C30 ve QLQ-MY20 anketleri kullan�lm�� ve sonu�lar istatistiksel olarak rapor edilmi�tir.
Bulgular: Hastalar�n 78�i (%46) kad�n, 90�� (%54) erkekti. Ortanca ya� 64 (22-84) idi. Bulgular incelendi�inde semptom �l�e�inde fonksiyonel �l�e�e g�re daha fazla etkinin oldu�u g�r�ld�.
Sonu�: B�t�nc�l tedavi y�netiminde, uygun tedavinin yeterli uygulanmas� ile birlikte tedaviye ba�l� yan etki y�netiminin �nemi, MM�li hastalar�n ya�am kalitesi a��s�ndan etkili fakt�rler olarak vurgulanm��t�r.

Anahtar Kelimeler: Multipl miyelom, ya�am kalitesi, kemoterapi

Corresponding Author: Ali �hsan GEM�C�, T�rkiye
Manuscript Language: English

CITE

Full Text PDF Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar